NewsRx

Search our medical news database

Anthrax Vaccine

LigoCyte awarded an additional $2.3M contract for mucosal anthrax vaccine

Published in Vaccine Weekly, August 2nd, 2006

LigoCyte Pharmaceuticals, Inc., announced that it has been awarded another contract from the U.S. Department of Defense (DOD) to continue the validation of their third-generation, mucosal anthrax vaccine.

The award for $2.3 million continues the DOD's support for the preclinical development of LigoCyte's intranasal, dual-antigen vaccine.

Protection data from LigoCyte's vaccine was recently reported in the May, 2006 journal Vaccine. The new vaccine provided 100% protection from an inhaled anthrax challenge in an animal study at Battelle Memorial Institute. "Our vaccine not only prevented death in all of the immunized animals, but it also...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook